Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.
… ProQR Announces R&D Day and Provides Update on Innovation Portfolio First Investor R&D Day on March 14, 2016 … amaurosis (LCA), today presents an update on the innovation pipeline and announces an R&D day for investors. …
… ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 … only by market approval of QR-110. Innovation credit (“Innovatiekrediet”) The Innovation Credit is awarded by the …
… ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision … at the 7th Annual Retinal Cell and Gene Therapy Innovation Summit being held Friday, April 29, 2022 and the … U.S. Presentations at the Retinal Cell and Gene Therapy Innovation Summit Presentation title: AON treatment for …
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board.
ProQR invented an entirely new way to treat genetic diseases. Axiomer enables RNA base editing by recruiting ADAR so your own body can treat disease. Learn more here.
… the pipeline behind the CF program from ProQR's internal innovation (discovery) unit and the Company intends to start … of QR-010. Horizon 2020 is one of the largest research and innovation programs in the European Union with nearly €80 …
… oligonucleotides for severe genetic diseases through our innovation unit.” Financial Highlights At June 30, 2016, … preclinical development of QR-110 and progress of our innovation programs such as QR-313 for epidermolysis bullosa, … behind the CF and LCA10 programs from ProQR’s internal innovation (discovery) unit. QR-010 received a Fast Track …
